Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambrisentan in Chinese Patients With PAH
NCT01808313Phase 3Completed
- Sponsor
- GSK
- Start
- Dec 2012
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ambrisentan in pulmonary arterial hypertension (PAH), sponsored by GSK. Started Dec 2012; status: completed.
02
Drugs
ambrisentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT01808313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01808313.